NKTX20261120C2.5
NKTX Nov 20 2026 2.50 Call (NKTX261120C00002500)
option OPRA

nkarta therapeutics seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies. nkarta was founded on the proprietary, robust and well characterized natural killer (nk) cell expansion technology pioneered by dario campana. the company is focused on leveraging the natural potent power of nk cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. nkarta is combining its nk expansion platform technology with proprietary cell engineering technologies to build differentiated autologous and allogeneic cell therapy candidates for the treatment of cancer. founded in 2015, the company's investors include sr one, nea and novo ventures. for more information, please visit the company's website at www.nkartatx.com.